8-K
filed December 16, 2025, 6:59 PM ET
ticker RBOT
CIK 0001812173
other material
confidence high
sentiment neutral
materiality 0.65
Vicarious Surgical guides FY2026 cash burn ~$35M (improved from $45M); NYSE to delist warrants
Vicarious Surgical Inc.
- FY2026 cash burn guidance of ~$35M, a $10M improvement over the recently updated $45M 2025 guidance.
- Additional cash needs beyond existing resources to achieve design freeze on Vicarious Surgical system are ~$25M.
- Design freeze targeted by year-end 2026; cost reductions from headcount and consulting partially offset by strategic outsourcing.
- NYSE to delist and immediately suspend trading in the Company's warrants (RBOT.WS) due to abnormally low price levels. No appeal.
- Entered into ATM agreement with H.C. Wainwright for potential sale of up to ~$2.3M of common stock (based on Form S-3 limitation); 3% commission.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-25-122267
- form_type
- 8-K
- ticker
- RBOT
- cik
- 0001812173
- company_name
- Vicarious Surgical Inc.
- filed_at
- 2025-12-16T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:40.549494+00:00
- generated_at
- 2026-05-16T13:05:15.594904+00:00
- sec_items
- ["1.01", "3.01", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-25-122267
- json_url
- https://secwatch.observer/filing/0001213900-25-122267.json
- markdown_url
- https://secwatch.observer/filing/0001213900-25-122267.md
- text_url
- https://secwatch.observer/filing/0001213900-25-122267.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/ea0269650-8k_vicarious.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 1.01, 3.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026
Filing page
SEC filing
GNLN
Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027
Greenlane Holdings, Inc.
April 27, 2026, 7:59 PM ET
other_material
Items 3.01, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice
(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)
indicating that Nasdaq s
Filing page
SEC filing
AGAE
AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K
Allied Gaming & Entertainment Inc.
May 21, 2026, 9:40 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: other_material
similar materiality
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
May 19, 2026, All In FutureTech Alliance,
Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)
from the Listing Qualifications Department (the “Staff”) of
Filing page
SEC filing
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
May 21, 2026, Tenon Medical, Inc. (the “Company”)
received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying
the Company that it is no longer in compliance with the
Filing page
SEC filing
SNYR
Synergy CHC receives Nasdaq delisting notice for bid price below $1.00
Synergy CHC Corp.
May 18, 2026, 9:01 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of
The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing
Filing page
SEC filing
HUMA
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Humacyte, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
May 4, 2026, Humacyte, Inc. (the “Company”)
received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification
that, for the 30 consecutive business days ended May 1, 2026, th
Filing page
SEC filing
XXI
Tether International acquires SoftBank's stake in Twenty One Capital; board members resign
Twenty One Capital, Inc.
May 20, 2026, 8:49 AM ET
other_material
Items 1.02, 3.01, 5.02, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01, 9.01
same event type: other_material
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
o independent directors, the minimum number required during the transition period
for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual
Filing page
SEC filing
PMI
Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity
Picard Medical, Inc.
May 11, 2026, 5:08 PM ET
other_material
Items 1.01, 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 1.01, 3.01, 9.01
same event type: other_material
This filing
YSE’s determination. Trading in the Company’s Common Stock will
be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock
remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of
the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,
and continued compliance with the NYSE’s other continued listing requirements.
Comparable filing
May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.